Antiplatelet Agents: P2Y12 Inhibitors – Test Prep and Practice Pearls
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
4.9 • 773 Ratings
🗓️ 26 February 2026
⏱️ 19 minutes
🧾️ Download transcript
Summary
P2Y12 inhibitors are a cornerstone of antiplatelet therapy in cardiovascular disease. These agents block the P2Y12 receptor on platelets, preventing ADP-mediated activation and reducing platelet aggregation. By inhibiting this amplification pathway, they help prevent arterial thrombosis in conditions such as acute coronary syndrome, percutaneous coronary intervention, stroke, and peripheral artery disease. The most commonly used oral agents include clopidogrel, prasugrel, and ticagrelor, each with important pharmacokinetic and clinical differences that influence agent selection.
From a pharmacist’s perspective, choosing the right P2Y12 inhibitor requires balancing ischemic benefit with bleeding risk. Clopidogrel requires CYP2C19 activation and is subject to drug interactions and genetic variability. Prasugrel provides more potent inhibition but carries a higher bleeding risk and is contraindicated in patients with prior stroke or TIA. Ticagrelor offers reversible inhibition but comes with unique considerations such as dyspnea and drug interactions via CYP3A4. Understanding these nuances allows pharmacists to optimize dual antiplatelet therapy and improve patient outcomes.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!
Support The Podcast and Check Out These Amazing Resources!
Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)
Guide to Drug Food Interactions (Amazon Best Seller)
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host pharmacist, Eric Christensen. |
| 0:05.2 | Thank you so much for listening today. Today I'm going to cover P2I-12 inhibitors. |
| 0:13.0 | But before we do that, I want to make sure to tell you to go check out real-life pharmacology.com. |
| 0:20.0 | Get your free 31-page PDF on the top 200 drugs. |
| 0:24.3 | It's a great study guide, great refresher, whether you're taking board exams or out in practice. |
| 0:28.9 | Definitely a no-brainer to go snag that. |
| 0:31.6 | Simply an email will get you access to that. |
| 0:35.7 | All right. |
| 0:36.4 | So let's get into the class of drugs I wanted to cover, |
| 0:40.4 | talking about P2Y12 inhibitors, some of the more common test prep pearls as well as things that |
| 0:47.2 | come up in practice. So this class, the meds I'm really going to focus on are clipidigrel, |
| 0:54.0 | brand name plavix |
| 0:55.0 | prasagrel brand name effiant and tycagrolor brand name berlinta there is |
| 1:02.5 | kangrelor as well as an iv only option in PCI associated with ACS but I'm not going to probably talk about that one too much. |
| 1:15.3 | You'll focus more so on the oral ambulatory care type medications. |
| 1:21.5 | All right, so let's talk a little bit about mechanisms and platelets. |
| 1:27.0 | And so this class is an anti-platelet class, category of agents. |
| 1:34.3 | So the P2Y-12 receptor, when that's activated, it stabilizes and causes platelet aggregation. |
| 1:44.6 | And so by using a P2y12 inhibitor, |
| 1:49.1 | we ultimately prevent that from happening, |
| 1:54.2 | and we cause platelets to not aggregate |
| 1:57.3 | and essentially thin the blood a little bit. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.